

Resource Summary Report

Generated by [RRID](#) on Sep 11, 2026

Survivin (71G4B7) Rabbit mAb

RRID:AB_2063948

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2808, RRID:AB_2063948

Antibody Information

URL: http://antibodyregistry.org/AB_2063948

Proper Citation: Cell Signaling Technology Cat# 2808, RRID:AB_2063948

Target Antigen: Survivin

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: W, IP, IHC-P, IHC-F, IF-IC, F

Consolidation on 11/2018: AB_10691694, AB_10827889, AB_2063948

Info: Used By NYUIHC-551.

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Survivin (71G4B7) Rabbit mAb

Description: This recombinant monoclonal targets Survivin

Target Organism: rat, mouse, human

Clone ID: Clone 71G4B7

Antibody ID: AB_2063948

Vendor: Cell Signaling Technology

Catalog Number: 2808

Record Creation Time: 20231110T070234+0000

Record Last Update: 20260831T203210+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Survivin (71G4B7) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 39 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

King JS, et al. (2026) Hemidesmosomes and Notch signaling regulate epidermal differentiation via delamination. *Development (Cambridge, England)*, 153(16).

Foidart P, et al. (2026) Whole-genome doubling drives immune evasion by silencing antigen presentation. *Cancer cell*, 44(7), 1418.

Näsiaho J, et al. (2026) Spatial single-cell analysis reveals tumor microenvironment signatures predictive of oral cavity cancer outcome. *Cell reports. Medicine*, 7(2), 102615.

Lemay SE, et al. (2025) Unraveling AURKB as a potential therapeutic target in pulmonary hypertension using integrated transcriptomic analysis and pre-clinical studies. *Cell reports. Medicine*, 6(2), 101964.

Canato S, et al. (2025) Survivin Promotes Stem Cell Competence for Skin Cancer Initiation. *Cancer discovery*, 15(2), 427.

Shawahny A, et al. (2025) An mTOR-Stat3-Stathmin pathway controls centrosome and microtubule dynamics for oocyte polarization. *Current biology : CB*, 35(24), 6054.

Boettcher L, et al. (2025) Retinoic acid-induced 2 deficiency impairs genomic stability in breast cancer. *Breast cancer research : BCR*, 27(1), 137.

Galindo-Moreno M, et al. (2025) Aurora B and INCENP co-overexpression severely disrupts mitosis and distinctly modifies the global transcriptional landscape. *iScience*, 28(6), 112731.

Zhu X, et al. (2025) Circular RNA circATM binds PARP1 to suppress Wnt/?-catenin signaling and induce cell cycle arrest in gastric cancer cells. *Journal of advanced*

research.

Matkar S, et al. (2025) Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma. *Molecular cancer therapeutics*, 24(9), 1389.

Zhang L, et al. (2025) Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer. *Cancer research*, 85(1), 134.

Koppenhafer SL, et al. (2025) Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells. *Cancer research communications*, 5(6), 1034.

Morshneva A, et al. (2025) An in vitro tumor recurrence model based on platinum-resistant colon cancer cells as a research tool for studying cancer cell dormancy. *PloS one*, 20(10), e0333671.

Stevenson L, et al. (2024) Inhibition of AKT enhances chemotherapy efficacy and synergistically interacts with targeting of the Inhibitor of apoptosis proteins in oesophageal adenocarcinoma. *Scientific reports*, 14(1), 32121.

Hedtfeld M, et al. (2024) A validation strategy to assess the role of phase separation as a determinant of macromolecular localization. *Molecular cell*, 84(9), 1783.

Hedtfeld M, et al. (2024) Protocol for validating liquid-liquid phase separation as a driver of membraneless organelle assembly in vitro and in human cells. *STAR protocols*, 5(4), 103410.

Gong Y, et al. (2023) Ex utero monkey embryogenesis from blastocyst to early organogenesis. *Cell*, 186(10), 2092.

Schaefer A, et al. (2023) RHOAL57V drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling. *Science signaling*, 16(816), eadg5289.

Savary C, et al. (2023) Fusion-negative rhabdomyosarcoma 3D organoids to predict effective drug combinations: A proof-of-concept on cell death inducers. *Cell reports. Medicine*, 4(12), 101339.

Ledvin L, et al. (2023) The anaphase-promoting complex controls a ubiquitination-phosphoprotein axis in chromatin during neurodevelopment. *Developmental cell*, 58(23), 2666.